Immunogenicity of a chimeric hepatitis A virus (HAV) carrying the HIV gp41 epitope 2F5

Antiviral Research

Volumn 73, Issue 2, 2007, Pages 101-111

  Kusov, Yuri Y ^a   Zamjatina, Natalja A ^b   Poleschuk, Valentina F ^b   Michailov, Michail I ^b   Morace, Graziella ^c   Eberle, Josef ^d   Gauss Müller, Verena ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti HIV; Guinea pig; Marmoset; Vaccine; Virus replication

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; GLYCOPROTEIN GP 41; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHIMERA; CONTROLLED STUDY; GUINEA PIG; HEPATITIS A VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MARMOSET; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIMATE; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS CARRIER; VIRUS LIKE AGENT; VIRUS REPLICATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CALLITHRIX; CELL LINE, TUMOR; EPITOPES; GUINEA PIGS; HEPATITIS A VACCINES; HEPATITIS A VIRUS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; VIRUS REPLICATION;

CAVIA; HEPATITIS A VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MARMOSETS; PRIMATES;

EID: 33846343262     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.08.003     Document Type: Article

References (48)

1. Anderson D.A., and Ross B.C. Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles. J. Virol. 64 (1990) 5284-5289
2. Andre F., Van Damme P., Safary A., and Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendation for use. Expert Rev. Vaccines 1 (2002) 9-23
3. Asher L.V., Binn L.N., Mensing T.L., Marchwicki R.H., Vassell R.A., and Young G.D. Pathogenesis of hepatitis A in orally inoculated owl monkeys (Aotus trivirgatus). J. Med. Virol. 47 (1995) 260-268
4. Barbato G., Bianchi E., Ingallinella P., Hurni W.H., Miller M.D., Ciliberto G., Cortese R., Bazzo R., Shiver J.W., and Pessi A. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into mechanism of neutralization and HIV fusion. J. Mol. Biol. 330 (2003) 1101-1115
5. Beneduce F., Kusov Y., Klinger M., Gauss-Müller V., and Morace G. Chimeric hepatitis A virus particles presenting a foreign epitope (HIV gp41) at their surface. Antiviral Res. 55 (2002) 369-377
6. Borovec S.V., and Anderson D.A. Synthesis and assembly of hepatitis A virus-specific proteins in BS-C-1 cells. J. Virol. 67 (1993) 3095-3102
7. Bradley D.W., Maynard J.E., Hindman S.H., Hornbeck C.L., Fields H.A., McCaustland K.A., and Cook Jr. E.H. Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. J. Clin. Microbiol. 5 (1977) 521-530
8. Cohen L., Benichou D., and Martin A. Analysis of deletion mutants indicates that the 2A polypeptide of hepatitis A virus participates in virion morphogenesis. J. Virol. 76 (2002) 7495-7505
9. Dotzauer A., Gebhardt U., Bieback K., Göttke U., Kracke A., Mages J., Lemon S.M., and Vallbracht A. Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via asialoglycoprotein receptor. J. Virol. 74 (2000) 10950-10957
10. Dotzauer A., Brenner M., Gebhardt U., and Vallbracht A. IgA-coated particles of hepatitis A virus are translocalized antivectorially from the apical to the basolateral site of polarized epithelial cells via the polymeric immunoglobulin receptor. J. Gen. Virol. 86 (2005) 2747-2751
11. Eberle J., and Seibl R. A new method for measuring reverse transcriptase activity by ELISA. J. Virol. Methods 40 (1992) 347-356
12. Eberle J., and Knopf C.W. Nonisotopic assays of viral polymerases and related proteins. Methods Enzymol. 275 (1996) 257-276
13. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., Katinger H., and Ruker F. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77 (1996) 2001-2008
14. Emerson S.U., Huang Y.K., Nguyen H., Brockington A., Govindarajan S.St., Clair M., Shapiro M., and Purcell R.H. Identification of VP1/2A and 2C as virulence genes of hepatitis A virus and demonstration of genetic instability of 2C. J. Virol. 76 (2002) 8551-8559
15. Finnegan C.M., Berg W., Lewis G.K., and DeVico A.L. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J. Virol. 76 (2002) 12123-12134
16. Gauss-Müller V., and Deinhardt F. Immunoreactivity of human and rabbit antisera to hepatitis A virus. J. Med. Virol. 24 (1988) 219-228
17. Harmon S., Emerson S.U., Huang Y.K., Summers D.F., and Ehrenfeld E. Hepatitis A viruses with deletions in the 2A gene are infectious in cultured cells and marmosets. J. Virol. 69 (1995) 5576-5581
18. Hornei B., Kammerer R., Moubayed P., Frings W., Gauss-Müller V., and Dotzauer A. Experimental hepatitis A virus infection in guinea pigs. J. Med. Virol. 64 (2001) 402-409
19. Jia X.Y., Summers D.F., and Ehrenfeld E. Host antibody response to viral structural and nonstructural proteins after hepatitis A infection. J. Infect. Dis. 165 (1992) 273-280
20. Jilg W., Bittner R., Bock H.L., Clemens R., Schatzl H., Schmidt M., Andre F.E., and Deinhardt F. Vaccination against hepatitis A: comparison of different short-term immunization schedules. Vaccine 1 (1992) 126-128
21. Kabrane-Lazizi Y., Emerson S.U., Herzog C., and Purcell R.H. Detection of antibodies to HAV 3C proteinase in experimentally infected chimpanzees and in naturally infected children. Vaccine 19 (2001) 2878-2883
22. Khudyakov Y.E., Lopareva E.N., Jue D.L., Fang S., Spelbring J., Krawczynski K., Margolis H.S., and Fields H.A. Antigenic epitopes of the hepatitis A virus polyprotein. Virology 260 (1999) 260-272
23. Kusov Y., and Gauss-Müller V. Improving proteolytic cleavage at the 3A/3B site of the hepatitis A virus polyprotein impairs processing and particle formation, and the impairment can be complemented in trans by 3AB and 3ABC. J. Virol. 73 (1999) 9867-9878
24. Kusov Y.Y., Gosert R., and Gauss-Müller V. Replication and in vivo repair of the hepatitis A virus genome lackung the poly(A) tail. J. Gen. Virol. 86 (2005) 1363-1368
25. Lehner T., Bergmeier L., Wang Y., Tao L., and Mitchell E. A rational basis for mucosal vaccination against HIV infection. Immunol. Rev. 170 (1999) 183-196
26. Malcolm B.A., Chin S.M., Jewell D.A., Stratton-Thomas J.R., Thudium K.B., Ralston R., and Rosenberg S. Expression and characterization of recombinant hepatitis A virus proteinase. Biochemistry 31 (1992) 3358-3363
27. Markel H. The search for effective HIV vaccines. New Engl. J. Med. 335 (2005) 753-757
28. Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F., Benvenuto E., and Capone I. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 75 (2001) 8434-8439
29. Matoba N., Magerus A., Geyer B.C., Zhang Y., Muralidharan M., Alfsen A., Arntzen C.J., Bomsel M., and Mor T.S. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 13584-13589
30. Mitchell L.A., and Galun E. Rectal immunization of mice with hepatitis A vaccine induces stronger systemic and local immune responses than parenteral immunization. Vaccine 21 (2003) 1527-1538
31. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., and Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68 (1994) 4031-4034
32. Pancharoen C., Mekmullica J., Thisyakorn U., Kasempimolporn S., Wilde H., and Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin. Infect. Dis. 41 (2005) 1537-1540
33. Probst C., Jecht M., and Gauss-Müller V. Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A. J. Biol. Chem. 274 (1999) 4527-4531
34. Pumpens P., Borisova G.P., Crowther R.A., and Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology 38 (1995) 63-74
35. Purcell R.H., Wong D.C., and Shapiro M. Relative infectivity of hepatitis A virus by the oral and intravenous routes in 2 species of nonhuman primates. J. Infect. Dis. 185 (2002) 1668-1671
36. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., and Katinger H. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 10 (1994) 1651-1658
37. Rachow A., Gauss-Müller V., and Probst C. Homogeneous hepatitis A virus particles Proteolytic release of the assembly signal 2A from procapsids by factor Xa. J. Biol. Chem. 278 (2003) 29744-29751
38. Schmidtke P., Habermehl P., Knuf M., Meyer C.U., Sanger R., and Zepp F. Cell mediated and antibody immune response to inactivated hepatitis A vaccine. Vaccine 23 (2005) 5127-5132
39. Shouval D., Ashur Y., Adler R., Lewis J.A., Armstrong M.E., Davide J.P., McGuire B., Kuter B., Brown L., Miller W., Elkana Y., and Nalin D.R. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis. Vaccine 1 (1993) 9-14
40. Schultz D.E., Honda M., Whetter L.E., McKnight K.L., and Lemon S.M. Mutations within the 5′ nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey cells. J. Virol. 70 (1996) 1041-1049
41. Sikuler E., Keynan A., Hanuka N., Friedman M.G., and Sarov I. Detection and persistence of specific IgA antibodies in serum of patients with hepatitis A by capture radioimmunoassay. J. Med. Virol. 11 (1983) 287-294
42. Sompayrac L. Hepatitis A virus-a virus that detours. How Pathogenic Viruses Work (2002), John and Bartlett Publishers, Boston, Toronto, London, Singapore pp. 46-49
43. Stewart D.R., Morris T.S., Purcell R.H., and Emerson S.U. Detection of antibodies to the nonstructural 3C proteinase of hepatitis A virus. J. Infect. Dis. 176 (1997) 593-601
44. Wang X.Y., Xu Z., Yao X., Tian M., Zhou L., He L., and Wen Y. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine 22 (2004) 1941-1945
45. Yang H.J., Chen M., Cheng T., He S.Z., Li S.W., Guan B.Q., Zhu Z.H., Gu Y., Zhang J., and Xia N.S. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World J. Gastroenterol. 11 (2005) 492-497
46. Yusibov V., Modelska A., Steplewski K., Agadjanyan M., Weiner D., Hooper D.C., and Koprowski H. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 5784-5788
47. Zamjatina N.A., Andjaparidze A.G., Balayan M.S., Sobol A.V., and Titova I.P. Susceptibility of Macaca rhesus monkey to hepatitis A virus strains isolated from man and monkeys. Vopr. Virusol. 1 (1990) 30-32
48. Zhao Y.L., Meng Z.D., Xu Z.Y., Guo J.J., Chai S.A., Duo C.G., Wang X.Y., Yao J.F., Liu H.B., Qi S.X., and Zhu H.B. H2 strain attenuated live hepatitis A vaccines: protective efficacy in a hepatitis A outbreak. World J. Gastroenterol. 6 (2000) 829-832